TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06121505

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: Patients will receive sintilimab combined with standard platinum-based doublet chemotherapy for a total of 4 cycles. Patients subsequently received maintenance treatment with sintilimab, and continued treatment until disease progression (PD), intolerable toxicity, withdrawal of informed consent, initiation of other anti-tumor treatments, death, or other circumstances that should stop treatment as specified in the protocol. Whichever occurs first. The maximum treatment time with sintilimab is 24 months (or 35 cycles).
Study: NCT05667649

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RB-ADSC
Description: Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RB-ADSC
Description: Ex Vivo Expanded, Autologous Adipose-Derived Stem Cells (ADSCs)
Study: NCT05015114

Intervention type: OTHER
Intervention: Sarcopenia Assessment
Description: Sarcopenia Assessment

Intervention type: OTHER
Intervention: Sarcopenia Assessment
Description: Sarcopenia Assessment
Study: NCT06037954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaires
Description: Patient demographic characteristics, Clinical variables, Cornell Service Index-Short Form (CSI), Patient Health Questionnaire-9 (PHQ-9), Generalized Anxiety Disorder scale-7 (GAD-7), Client Satisfaction Questionnaire (CSQ-8), Intention to Seek Help Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Severity Scale, Health Beliefs about Mental Illness Instrument (HBMII) - Emotional/Nervous Benefits Scale, Barriers to Mental Health Services Scale-Revised, Cues to action, Self-Efficacy to Seek Mental Health Care (SE-SMHC)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interviews
Description: Interviews will be conducted by the qualitative methods specialist and trained study staff and will last 30-45 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 30-minute telephone or videoconference sessions
Description: Includes five components delivered in three 30-minute telephone or videoconference visits over six weeks and one booster telephone call. All sessions are audio-recorded. The five components are:~1. Provide education about depression and treatment options~2. Identify treatment preferences and a personal goal achievable with mental health care~3. Assess barriers to treatment initiation~4. Recommend a referral using standardized referral options~5. Address barriers to accessing care
Study: NCT05204563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of Imipenem/Cilastatin and XNW4107
Description: Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipenem/Cilastatin/Relebactam
Description: Imipenem/Cilastatin/Relebactam 1.25 g for Injection
Study: NCT05920213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycols
Description: 280g/ 24 hours for 5 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactulose oral solution
Description: 60-120 ml per day for 5 days
Study: NCT06061159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remimazolam besylate
Description: initial dose is 0.2mg/kg；adjust dosage is 0.05mg/kg
Study: NCT04935619

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency Reinforcement
Description: Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Non-Contingency Reinforcement
Description: Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.
Study: NCT05563974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family led postnatal care
Description: Family-led Postnatal Care-FPNC A midwife involves families and uses a visual checklist to assess and counsel. The midwife then gives families the checklist and guides them how to retrieve a home care kit that has a blood pressure machine, infrared thermometer, and health education booklet.~At home, families assess the health of postnatal mothers and newborns for 6 days, and then return the completed checklist and home care kit to the community location.
Study: NCT06460909

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychological support
Description: An interview with the psychologist before surgery.
Study: NCT05239468

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate 100 mg
Description: One tablet of bezafibrate 100 mg IR once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 100 mg
Description: One tablet of bezafibrate 100 mg IR once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate 200 mg
Description: Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 mg
Description: Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate 200 mg
Description: Two tablets of bezafibrate 200 mg IR once daily for BZF 400 mg IR
Study: NCT05290298

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NITRATE
Description: Multi-component nutritional formula

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Placebo
Study: NCT05239468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid 5 mg
Description: One tablet of obeticholic acid 5 mg tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid 5 mg
Description: One tablet of obeticholic acid 5 mg tablet once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeticholic Acid 5 mg
Description: One tablet of obeticholic acid 5 mg tablet once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic Acid placebo
Description: One tablet of obeticholic acid placebo tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obeticholic Acid placebo
Description: One tablet of obeticholic acid placebo tablet once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bezafibrate Placebo
Description: One tablet of bezafibrate placebo tablet once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bezafibrate Placebo
Description: One tablet of bezafibrate placebo tablet once daily
Study: NCT06015945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Acustimulation (TEA)
Description: The severity and frequency participants pain will be measured during a run-in period of 2 weeks with to assess baseline pain severity and frequency. Eligible participants will have a 4-week treatment period at home. Stimulation with the TEA device will be performed for 30 minutes twice per day, in the morning and in the evening.~In addition to using the device, participants will have study visits, complete surveys, as well as provide medical information during the study.
Study: NCT05551741

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC-Ab002
Description: An anti-PD-L1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC-Ab002
Description: An anti-PD-L1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC-Ab002
Description: An anti-PD-L1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC-Ab002
Description: An anti-PD-L1 monoclonal antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IBC-Ab002
Description: An anti-PD-L1 monoclonal antibody

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Normal Saline
Study: NCT04987229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OLZ/SAM
Description: Olanzapine and Samidorphan fixed dose coated tablet taken once daily
Study: NCT05480696

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fructo-oligosaccharide enriched inulin supplement
Description: Experiment

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Maltodextrin
Description: Placebo.
Study: NCT06638879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Participants will receive a tacrolimus treatment via toothpaste application twice daily for three months.
Study: NCT05633667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (ZIM)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (ZIM)
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zimberelimab (ZIM)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (ZIM)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (ZIM)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (ZIM)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (ZIM)
Description: Administered intravenously
Study: NCT05920213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose oral solution
Description: 60-120 ml per day for 5 days
Study: NCT05633667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab (ZIM)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab (DOM)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab (DOM)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domvanalimab (DOM)
Description: Administered intravenously
Study: NCT05920213

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactulose oral solution
Description: 60-120 ml per day for 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-ornithine L-aspartate
Description: 30g/24 hours in 3 divided doses for 5 days
Study: NCT05633667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sacituzumab govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab govitecan-hziy (SG)
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant (ETRUMA)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant (ETRUMA)
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etrumadenant (ETRUMA)
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously
Study: NCT06003959

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine nursing care
Description: Preterm infants in the control group did not receive any intervention other than the routine feeding protocol applied in the clinic.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breastfeeding support system
Description: The body weight of preterm infants in the experimental group was measured and recorded each morning before their first feeding. Mothers of these infants were asked to complete the Mother-Infant Attachment Scale (MIAS) prior to the procedure. The physician determined the appropriate amount of breast milk the infant should receive during feeding. Before each feeding, the neonatal nurse ensured the sterile preparation of the milk and transferred it to the Breastfeeding Support System. The mothers were then prepared for the procedure, with the neonatal nurse explaining how the breastfeeding support system worked. Once both the mother and baby were ready, the baby was placed at the mother's breast. After feeding, the mothers were asked to complete the MIAS again.
Study: NCT06061445

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Radiotherapy combined with TKI and Anti-PD-1 Antibody
Description: After signing informed consent, patients received Anti-PD-1 Antibody 200 mg intravenously on the first day of each cycle, Q3W; Tyrosine Kinase Inhibitor (TKI) was administration started on the first and continually administered until disease progression developed or serious treatment-related toxicity occurred; Cancer thrombus radiotherapy treatment: For the portal vein cancer thrombus site (Total dose 25-30Gy, times 5-6) , Treatment usually starts within 7 days and ends within 1 week after the first cycle of injection of anti PD-1 inhibitors.
Study: NCT04558502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride capsule
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minocycline hydrochloride capsule
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colloidal bismuth pectin
Description: Gastric mucosal protective drug with anti-H. pylori effect

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esomeprazole
Description: Proton pump inhibitor
Study: NCT05641649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate and valproic acid extended release tablet
Description: Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium valproate and valproic acid extended release tablet
Description: Test or innovator tablet formulation of sodium valproate and valproic acid will be administered orally to the volunteers on each study days in fasting condition. Volunteers will be receiving a single tablet of either of the formulations on the study days by a randomization technique so that each of them receives both formulations during the study period.
Study: NCT06427447

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Description: Upfront chemotherapy (gemcitabine plus capecitabine) followed chemoradiotherapy (radiotherapy with concurrent capecitabine)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant chemotherapy
Description: Chemotherapy (gemcitabine plus capecitabine)
Study: NCT06062498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elacestrant, palbociclib, abemaciclib, ribociclib
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elacestrant, palbociclib, abemaciclib, ribociclib
Description: Given orally
Study: NCT06559982

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brown seaweed and tart cherry blend
Description: Blend of brown seaweed and tart cherry blend taken twice daily

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical in taste and colour to the supplement, but with no brown seaweed or tart cherry.
Study: NCT06356766

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telerehabilitation
Description: Modified Duran Protocol via Telerehabilitation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Face-to-face rehabilitation
Description: Modified Duran Protocol
Study: NCT05643976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KardioPAC Mobile Application
Description: Like those in the SOC CR arm, participants assigned to the CR+KardioPAC arm will receive standard of care and attend CR as prescribed by their physician. Additionally, they will receive access to the digital app, KardioPAC, \& a BP device for home use that will record their BP readings in the app.~KardioPAC is a remote patient monitoring system that allows providers to monitor patients and send out daily reminders. It integrates with BP monitors and fitness watches to collect patient health information at home. The information is uploaded to the HIPAA-compliant server and presented on the website for providers to read. Its reminder system can be customized to meet diverse clinical needs.~Lastly, the Kura Care in-house Registered Nurse will provide 20-30 min of health coaching to intervention arm participants on a weekly or bi-weekly basis via the app. The coaching will include greetings, review of medication adherence, encouragement to exercise, and symptom management, if applicable.
Study: NCT05633667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Administered intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Administered intravenously
Study: NCT06460168

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan(MWM) MobilizationTechnique
Description: Mulligan Mobilization program in MWM , a therapist-applied pain free accessory gliding force combined with active movement.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session) No of repetitions; 3 sets for 10 repetitions with 1 minute rest between sets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maitland Mobilization technique
Description: will receive (Maitland mobilization program manipulative physiotherapy in which chain of oscillatory joint mobilization grades l-lV based on the pathological limit of tissue are used) In this, the exercises will be performed in 3 sets and 10 repetitions with 5-10s hold and 30s to 1min rest between repetitions.~No Of Sessions Per Week: 3 Per Weeks for 6 weeks (50 Min per Session)
Study: NCT05059470

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV